Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Comment by made2laston Aug 23, 2017 5:27pm

242 Views

Post# 26614291

RE:Fourth Patient was treated with full dose on July 20th

Hi SizzlinSteaks;

I like to think things all the way through, including taking a realistic hard look at the downside possibilities. I believe that Theralase would be taking a totally unnecessary and very serious risk to issue one PR for each patient. It is much safer stance to issue one bulk PR after all six high dose people have had their C-T scans done.

Here's why. Say for example, we treated all six people in rapid succession and had an overall 4 out of 6 success rate, but the first two people were fails. How hard would the company be hit if the first two patients in a row were PR'd as fails? The news would devastate the share price and demoralize the longs. We would find it impossible to raise capital at that point, putting the whole company at risk of continuation. The shorts would have a field day. How many people would then abandon their winning investment because they never held on to see that the next four people in a row did very well?

How about issuing one positive PR stating that 4 of 6 patients did very well, 2/3's, a 67% success rate. We are the champions, bask in the glory and riches of our success, and we survive to continue on to many more great things.

Now, how do you want to see Theralase handle patient PR's?

Thanks;

made2last